5-(3-methylphenoxy)-2(1h)-pyrimidinone and Insulin Resistance

5-(3-methylphenoxy)-2(1h)-pyrimidinone has been researched along with Insulin Resistance in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Block, B; Cha, BS; Chung, CH; Frias, JP; Greenway, F; Kim, BJ; Kim, SG; Lee, MK; Lee, SH; Moon, MK; Park, HK; Rhee, SY; Watkins, E	1

Trials

1 trial(s) available for 5-(3-methylphenoxy)-2(1h)-pyrimidinone and Insulin Resistance

Article	Year
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus. Journal of diabetes and its complications, 2020, Volume: 34, Issue:5 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Pyrimidinones; src-Family Kinases; Treatment Outcome; Young Adult	2020

Article

Year

A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.

Journal of diabetes and its complications, 2020, Volume: 34, Issue:5

Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Pyrimidinones; src-Family Kinases; Treatment Outcome; Young Adult

2020